All In Biotech

Drug Trial Radar · NCT02933606

Phase II Study of BNC210 in PTSD

A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).

Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 193 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

193

Actual

Start

Jun 30, 2016

Primary completion

Jul 5, 2018

Study completion Jul 25, 2018

Sponsor

Lead sponsor
Bionomics LimitedIndustry
Sponsor type
Industry
First posted
Oct 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

  • BNC210Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity ScoreTime frame: 12 weeks.

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Oceanside, California

  • Site not named

    Rancho Mirage, California

  • Site not named

    Redlands, California

  • Site not named

    Riverside, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lauderhill, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Oakland Park, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Overland Park, Kansas

  • Site not named

    New Bedford, Massachusetts

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Berlin, New Jersey

  • Site not named

    Canton, Ohio

  • Site not named

    Memphis, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Penrith, New South Wales, Australia

  • Site not named

    Auchenflower, Queensland, Australia

  • Site not named

    Toowong, Queensland, Australia

  • Site not named

    Elizabeth Vale, South Australia, Australia

  • Site not named

    St Kilda, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.